https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2781 Wed 24 Jul 2013 22:53:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30985 Wed 11 Apr 2018 14:34:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20768 P < 0.05), and reduced the expression levels of p-AKT, p-FAK, MMP-2, MMP-9, TIMP-1, TIMP-2, MMP-2/ TIMP-2 and MMP-9/TIMP-1 proteins (all P < 0.05). Conclusion: Over-expression of PIB5PA can inhibit the abilities of migration and invasion of human melanoma Mel-FH cells in vitro , which may be associated with inactivity of AKT and FAK, and down-regulation of the relative expression levels of MMP-2/TIMP-2 and MMP-9/TIMP-1.]]> Wed 11 Apr 2018 10:29:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33092 Wed 04 Sep 2019 09:56:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34053 Wed 04 Sep 2019 09:39:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8304 Sat 24 Mar 2018 08:40:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1891 Sat 24 Mar 2018 08:33:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1966 Sat 24 Mar 2018 08:33:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1508 Sat 24 Mar 2018 08:30:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1805 Sat 24 Mar 2018 08:27:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3185 Sat 24 Mar 2018 07:18:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46079 50 currently under investigation. These compounds inhibit biological targets spanning protein kinases, STAT3, BET, HDACs and Bcl-2 family proteins. Unsurprisingly, protein kinase inhibitors are overrepresented. Some trials show promise; a phase I combination trial of vorinostat 11 and capecitabine 17 gave a median overall survival (MoS) of 13 months and a phase II study of pazopanib 15 showed a MoS of 25 months. The current standard of care for metastatic pancreatic ductal adenocarcinoma, fluorouracil/folic acid (5-FU, Adrucil®), and gemcitabine (GEMZAR®) afforded a MoS of 23 and 23.6 months (EPAC-3 study), respectively. In patients who can tolerate the FOLFIRINOX regime, this is becoming the standard of treatment with a MoS of 11.1 months. Clinical study progress has been slow with limited improvement in patient survival relative to gemcitabine 1 monotherapy. A major cause of low PC survival is the late stage of diagnosis, occurring in patients who consider typical early stage warning signs of aches and pains normal. The selection of patients with specific disease phenotypes, the use of improved efficient drug combinations, the identification of biomarkers to specific cancer subtypes and more effective designs of investigation have improved outcomes. To move beyond the current dire condition and paucity of PC treatment options, determination of the best regimes and new treatment options is a challenge that must be met. The reasons for poor PC prognosis have remained largely unchanged for 20 years. This is arguably a consequence of significant changes in the drug discovery landscape, and the increasing pressure on academia to deliver short term ‘media’ friendly short-term news ‘bites’. PC research sits at a pivotal point. Perhaps the greatest challenge is enacting a culture change that recognises that major breakthroughs are a result of blue sky, truly innovative and curiosity driven research.]]> Fri 11 Nov 2022 10:04:19 AEDT ]]>